UNLABELLED: The superior patency of ITA grafts to saphenous veins is conclusive. The aim of the study was to collate mid-term benefit between patients receiving bilateral ITA (BITA) or single ITA (SITA). Outcome of 1378 pts with isolated CABG operated between 1/97-8/99 was analyzed retrospectively. Follow-up was 4.0 to 6.6 years (average 5.3). A total of 716 pts received BITA, 662 SITA and additional saphenous veins. We evaluated mortality rate, freedom from reoperation, intervention (PTCA/stent), and incidence of cardiac events and quality of life with respect to pts risk factors. Demographic data: Male gender was more frequent in both groups (BITA females: n=115; males: n=601; SITA females: n=150; males: n=512; p<0.01). Mean age was comparable in both groups with 69.2 years (42.7 to 88.6 years) in the BITA group and 71.0 years (47.3 to 91.6 years) (n. s.) in the SITA group. RISK FACTORS: Incidence of diabetes mellitus (26.0 vs 25.9%) as well as the mean BMI (27.4 vs 27.0%) did not differ statistically in both groups. RESULTS: Clinical characteristics like NYHA/ CCS classifications showed a significant difference towards superior results only for stadium I in the BITA group. Mortality/cardiac events after 5.3 years average: Total mortality revealed 5.2% (n=37) in the BITA vs 9.1% (n=60) in the SITA group (p</=0.005). The cardiac-related mortality was 0.7% (n=5) in the BITA and 2.0% (n=13) in the SITA group (p<0.05). The non-cardiac-related mortality did not differ significantly (2.7 vs 2.9%). The incidence of redo-operations was 0.1% (BITA) vs 0.6% (SITA) (n. s). Cardiac interventions like PTCA or stent were performed in 3.1% (BITA) vs 4.7% (SITA) or 3.7% (BITA) vs 4.2% (SITA) (n. s.) respectively. Infarction-rate was 2.0% in the BITA and 3.0% in the SITA group (n. s.). CONCLUSIONS: Mid- to long-term benefit of patients receiving bilateral ITA is superior to those with single ITA. Cardiac-related mortality and incidence of reoperation was reduced to less than half after BITA grafting. Freedom from cardiac interventions (PTCA/stent), NYHA/CCS classifications and quality of life were rarely influenced by BITA frequency.
UNLABELLED: The superior patency of ITA grafts to saphenous veins is conclusive. The aim of the study was to collate mid-term benefit between patients receiving bilateral ITA (BITA) or single ITA (SITA). Outcome of 1378 pts with isolated CABG operated between 1/97-8/99 was analyzed retrospectively. Follow-up was 4.0 to 6.6 years (average 5.3). A total of 716 pts received BITA, 662 SITA and additional saphenous veins. We evaluated mortality rate, freedom from reoperation, intervention (PTCA/stent), and incidence of cardiac events and quality of life with respect to pts risk factors. Demographic data: Male gender was more frequent in both groups (BITA females: n=115; males: n=601; SITA females: n=150; males: n=512; p<0.01). Mean age was comparable in both groups with 69.2 years (42.7 to 88.6 years) in the BITA group and 71.0 years (47.3 to 91.6 years) (n. s.) in the SITA group. RISK FACTORS: Incidence of diabetes mellitus (26.0 vs 25.9%) as well as the mean BMI (27.4 vs 27.0%) did not differ statistically in both groups. RESULTS: Clinical characteristics like NYHA/ CCS classifications showed a significant difference towards superior results only for stadium I in the BITA group. Mortality/cardiac events after 5.3 years average: Total mortality revealed 5.2% (n=37) in the BITA vs 9.1% (n=60) in the SITA group (p</=0.005). The cardiac-related mortality was 0.7% (n=5) in the BITA and 2.0% (n=13) in the SITA group (p<0.05). The non-cardiac-related mortality did not differ significantly (2.7 vs 2.9%). The incidence of redo-operations was 0.1% (BITA) vs 0.6% (SITA) (n. s). Cardiac interventions like PTCA or stent were performed in 3.1% (BITA) vs 4.7% (SITA) or 3.7% (BITA) vs 4.2% (SITA) (n. s.) respectively. Infarction-rate was 2.0% in the BITA and 3.0% in the SITA group (n. s.). CONCLUSIONS: Mid- to long-term benefit of patients receiving bilateral ITA is superior to those with single ITA. Cardiac-related mortality and incidence of reoperation was reduced to less than half after BITA grafting. Freedom from cardiac interventions (PTCA/stent), NYHA/CCS classifications and quality of life were rarely influenced by BITA frequency.
Authors: B W Lytle; E H Blackstone; F D Loop; P L Houghtaling; J H Arnold; R Akhrass; P M McCarthy; D M Cosgrove Journal: J Thorac Cardiovasc Surg Date: 1999-05 Impact factor: 5.209
Authors: E Berreklouw; P P Rademakers; J M Koster; L van Leur; B J van der Wielen; P Westers Journal: Ann Thorac Surg Date: 2001-11 Impact factor: 4.330
Authors: A C Fiore; K S Naunheim; P Dean; G C Kaiser; G Pennington; V L Willman; L R McBride; H B Barner Journal: Ann Thorac Surg Date: 1990-02 Impact factor: 4.330
Authors: Mario Gaudino; Antonino Di Franco; Mohamed Rahouma; Derrick Y Tam; Mario Iannaccone; Saswata Deb; Fabrizio D'Ascenzo; Ahmed A Abouarab; Leonard N Girardi; David P Taggart; Stephen E Fremes Journal: J Am Heart Assoc Date: 2018-01-06 Impact factor: 5.501
Authors: Mario Gaudino; Faisal Bakaeen; Umberto Benedetto; Mohamed Rahouma; Antonino Di Franco; Derrick Y Tam; Mario Iannaccone; Thomas A Schwann; Robert Habib; Marc Ruel; John D Puskas; Joseph Sabik; Leonard N Girardi; David P Taggart; Stephen E Fremes Journal: J Am Heart Assoc Date: 2018-05-17 Impact factor: 5.501